D. Mcleod

发表

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

P. Goodman, E. Crawford, M. A. Davis, 1989, The New England journal of medicine.

PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer.

M. Augustus, F. Mostofi, V. Srikantan, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Silencing of lactotransferrin expression by methylation in prostate cancer progression

V. Srikantan, S. Srivastava, I. Sesterhenn, 2007, Cancer biology & therapy.

Clinical potential of the ERG oncoprotein in prostate cancer

Isabell A. Sesterhenn, David G. McLeod, S. Srivastava, 2012, Nature Reviews Urology.

Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer*

D. Mcleod, S. Brassell, I. Rosner, 2005, Current opinion in urology.

Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.

Wei Zhang, F. Mostofi, J. Moul, 1999, The Journal of urology.

Introduction to artificial neural networks for physicians: Taking the lid off the black box

P. Snow, D. Mcleod, D. Rodvold, 2001, The Prostate.

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.

J W Moul, F. Mostofi, J. Moul, 1996, The Journal of urology.

p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.

J. Moul, J. Bauer, I. Sesterhenn, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer.

J. Moul, S. Srivastava, R. Connelly, 1999, Urology.

Success and failure of single-modality treatment for early prostate cancer.

D. Mcleod, 2004, Reviews in urology.

Immediate Therapy in Early Prostate Cancer: Results from the Bicalutamide (‘Casodex’) EPC Programme

M. Wirth, W. See, P. Iversen, 2002 .

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

T. Tammela, J. Montie, M. Wirth, 2002, The Journal of urology.

Management Options for Gynaecomastia and Breast Pain Associated with Nonsteroidal Antiandrogen Therapy

D. Gillatt, M. Wirth, W. See, 2012, Clinical drug investigation.

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation

S. Srivastava, I. Sesterhenn, I. Sesterhenn, 2008, Oncogene.

Age-specific reference ranges for serum prostate-specific antigen in black men.

J. Moul, W. Mccarthy, D. Mcleod, 1996, The New England journal of medicine.

Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens

T. Werner, I. Sesterhenn, M. Seifert, 2008, Prostate Cancer and Prostatic Diseases.

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

Timothy F. Donahue, J. Moul, C. Amling, 2004, The Journal of urology.

Indium-111-capromab pendetide scans: an important test relevant to clinical decision making.

O. Sartor, D. Mcleod, 2001, Urology.

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.

Jason C. Massengill, Timothy F. Donahue, J. Moul, 2003, The Journal of urology.

Original Articles PRETREATMENT TOTAL TESTOSTERONE LEVEL PREDICTS PATHOLOGICAL STAGE IN PATIENTS WITH LOCALIZED PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY

Jason C. Massengill, J. Moul, C. Amling, 2003 .

Defining the role of antiandrogens in the treatment of prostate cancer.

D. Mcleod, G. Kolvenbag, 1996, Urology.

Hormonal therapy in the treatment of carcinoma of the prostate

D. Mcleod, D. Mcleod, David G. Mcleod, 1995 .

Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.

J. Moul, S. Srivastava, I. Sesterhenn, 1994, Cancer research.

Intracranial metastases in prostate cancer

B. Miles, D. Mcleod, H. G. Taylor, 1984, Cancer.

Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database.

J. Moul, C. Amling, W. Sexton, 2003, Urologic oncology.

Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database.

J. Moul, C. Amling, W. Sexton, 2002, Surgery.

Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.

J. Moul, S. Srivastava, R. Connelly, 1999, The Journal of urology.

The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?

J. Moul, S. Srivastava, J. Bauer, 1996, Urology.

Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low‐volume tumors

J. Moul, S. Srivastava, I. Sesterhenn, 2010, Pathology international.

Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?

I. Sesterhenn, C. Davis, D. Mcleod, 2008, Journal of Clinical Pathology.

Negative pressure devices in the explanted penile prosthesis population.

J. Moul, D. Mcleod, 1989, The Journal of urology.

The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma

D. Ornstein, S. Srivastava, I. Sesterhenn, 2009, The Prostate.

Expression during Prostate Cancer Progression Exhibits Cell Growth Inhibitory Function and Decreased PMEPA 1 , an Androgen-regulated NEDD 4-binding Protein

Wei Zhang, J. Moul, S. Srivastava, 2003 .

PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression.

Wei Zhang, J. Moul, S. Srivastava, 2003, Cancer research.

Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research.

J. Moul, C. Amling, C. Kane, 2002, Radiology.

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2020, Journal of Translational Medicine.

Leuprolide With and Without Flutamide in Advanced Prostate Cancer

P. Goodman, E. Crawford, M. A. Davis, 1990, Cancer.

Ureteral carcinoma presenting as a complex pelvic mass in a post menopausal patient.

D. Mcleod, C. Harrison, J. Farley, 1998, Gynecologic oncology.

The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL.

J. Moul, D. Mcleod, Hongyu Wu, 2002, Urologic oncology.

Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era

J. Bishoff, J. Moul, C. Kane, 2001 .

Improvements in pathologic staging for African‐American men undergoing radical retropubic prostatectomy during the prostate specific antigen era

Laurence R. Paquette, J. Moul, R. Connelly, 2001, Cancer.

A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group

J. Moul, C. Kane, J. Thrasher, 2001, BJU international.

Treatment of clinically organ confined prostate cancer.

D. Mcleod, 1999, Scandinavian journal of urology and nephrology. Supplementum.

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

P. Scardino, S. Loening, G. Murphy, 1983, Cancer.

Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer.

P. Scardino, S. Loening, G. Murphy, 1983, The Journal of urology.

A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area.

P. Scardino, S. Loening, G. Murphy, 1983, The Journal of urology.

Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer.

E D Crawford, B E Hillner, E. Crawford, 1995, Urology.

The use of flutamide in hormone‐refractory metastatic prostate cancer

E. Crawford, D. Spicer, E. Crawford, 1990, Cancer.

The emergence of radioimmunoscintigraphy for prostate cancer.

D. Mcleod, T. Keane, I. Rosner, 2006, Reviews in urology.

Watchful waiting and factors predictive of secondary treatment of localized prostate cancer.

Timothy F. Donahue, J. Moul, C. Amling, 2004, The Journal of urology.

Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center

J. Moul, J. Bauer, R. Connelly, 2002, Prostate Cancer and Prostatic Diseases.

Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients

J. Bishoff, F. Mostofi, J. Moul, 2002, Prostate Cancer and Prostatic Diseases.

7. RIU0472_07-31.qxd

D. Mcleod, S. Brassell, K. Rice, 2010 .

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

M. Wirth, W. See, P. Iversen, 2006, BJU international.

Allelic loss on chromosome 6Q in primary prostate cancer

F. Mostofi, V. Srikantan, J. Moul, 1999, International journal of cancer.

Efficacy of radiographic chest imaging in patients with testicular cancer.

J. Moul, D. Mcleod, E. Colón, 1994, Urology.

Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.

Timothy F. Donahue, J. Moul, C. Amling, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of DNA ploidy in carcinoma of prostate.

R. E. Cunningham, J. Moul, J. Lynch, 1989, Urology.

Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.

M. Wirth, W. See, H. Payne, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Long‐term overall survival and metastasis‐free survival for men with prostate‐specific antigen‐recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database

E. Antonarakis, M. Eisenberger, Yongmei Chen, 2011, BJU international.

Advances in Brief PSGR , a Novel Prostate-specific Gene with Homology to a G Protein-coupled Receptor , Is Overexpressed in Prostate Cancer 1

Wei Zhang, M. Augustus, V. Srikantan, 2000 .

Cancer Protein-coupled Receptor , Is Overexpressed in Prostate , a Novel Prostate-specific Gene with Homology to a G PSGR Updated

M. Augustus, V. Srikantan, J. Moul, 2000 .

Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers

S. Srivastava, I. Sesterhenn, Hua Li, 2021, Frontiers in Oncology.

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

F. Mostofi, J. Moul, S. Srivastava, 1995, JAMA.

Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?

M. Wirth, W. See, G. Chodak, 2006, The Journal of urology.

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

S. Steinberg, J. Trepel, W. Figg, 2016, BJU international.

Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.

T. Brand, A. Metwalli, Yongmei Chen, 2014, Urologic oncology.

Prostate cancer marker panel with single cell sensitivity in urine

S. Srivastava, I. Sesterhenn, G. Petrovics, 2015, The Prostate.

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues

P. Schellhammer, N. Vogelzang, M. Soloway, 1999, The Prostate.

Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036.

E. Crawford, M. Benson, M. Eisenberger, 1994, Seminars in oncology.

EDITORIAL: PROSTATE CANCER DIAGNOSIS

D. Mcleod, 1995 .

New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches.

J. Moul, D. Bajorin, D. Petrylak, 2011, Urology.

Differences in the frequency of ERG oncoprotein expression between index tumors of Caucasian American and African American prostate cancer patients

S. Srivastava, S. Perner, D. Pfister, 2012 .

Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study.

J. Ellis, D. Stablein, R. Weiss, 1991, The Journal of urology.

Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients.

J. Moul, S. Srivastava, R. Connelly, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Controversies in the treatment of metastatic prostate cancer

E. Crawford, M. Eisenberger, D. Mcleod, 1992, Cancer.

Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer.

S. Srivastava, D. Mcleod, 2017, European urology.

Diagnostic potential of serum proteomic patterns in prostate cancer.

Bao-Ling Adam, Amina Ali, J. Moul, 2003, The Journal of urology.

A Feedback Loop between the Androgen Receptor and a NEDD4-binding Protein, PMEPA1, in Prostate Cancer Cells*

S. Srivastava, Hongyun Li, D. Mcleod, 2008, Journal of Biological Chemistry.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

V. Srikantan, J. Moul, S. Srivastava, 2006, Oncogene.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens

P. Schellhammer, J. Moul, C. Higano, 2018, The Journal of urology.

Effect of exogenous testosterone replacement on prostate‐specific antigen and prostate‐specific membrane antigen levels in hypogonadal men

R. Connelly, G. Murphy, D. Mcleod, 1995, Journal of surgical oncology.

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.

N. Dawson, D. Mcleod, David G. Mcleod, 1995, The Journal of urology.

Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections.

J. Moul, D. Mcleod, D. Peppas, 1992, The Journal of urology.

Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.

G. Peoples, D. Mcleod, C. Ioannides, 2009, Journal of the American College of Surgeons.

How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium.

S. Fosså, G. Steineck, P. Ekman, 1997, Urology.

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

T. Tammela, J. Montie, M. Wirth, 2002, The Journal of urology.

Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

G. Peoples, D. Mcleod, C. Ioannides, 2005, Clinical Cancer Research.

Phase IClinical Trial of a HER-2 / neu Peptide ( E 75 ) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

G. Peoples, D. Mcleod, C. Ioannides, 2005 .

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN

S. Srivastava, I. Sesterhenn, Hua Li, 2015, Oncotarget.

Molecular implications of the antiandrogen withdrawal syndrome.

J. Moul, D. Mcleod, S. Srivastava, 1995, Seminars in urology.

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.

A. D'Amico, P. Carroll, Ming-Hui Chen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation.

J. Moul, S. Srivastava, Y. Tong, 1995, Urology.

The liver scan in urologic oncology.

D. Mcleod, M. Mood, R. Stutzman, 1980, The Journal of urology.

The influence of nodal status on progression outcomes in patients with prostate cancer: Data from the Early Prostate Cancer program at 7.4 years.

M. Wirth, W. See, P. Iversen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.

T. Tammela, J. Johansson, J. Montie, 2004, Urology.

Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (PTS) with stage D2 adknocarcinoma of the prostate (CAP): Results of NCI ntergroup study 0105 (SWOG and ECOG)

E. Crawford, M. Eisenberger, D. Mcleod, 1997 .

The role of retroperitoneal lymphadenectomy in mature teratoma of the testis.

F. Mostofi, J. Moul, U. Engelmann, 1997, The Journal of urology.

Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors.

J. Moul, D. Mcleod, J. Foley, 1994, Urology.

Management of Disseminated Prostate Cancer

P. Carroll, C. Wood, H. Scher, 2003 .

The effective management of biochemical recurrence in patients with prostate cancer.

D. Mcleod, 2005, Reviews in urology.

Emerging role of adjuvant hormonal therapy.

D. Mcleod, 2002, Urology.

Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy.

J. Moul, S. Srivastava, J. Bauer, 1998, Urology.

Radical prostatectomy with pelvic lymphadenectomy: observations on the accuracy of staging with lymph node frozen sections.

D. Mcleod, J. Fowler, R. Stutzman, 1981, The Journal of urology.

The bicalutamide Early Prostate Cancer Program. Demography.

M. Wirth, W. See, P. Iversen, 2001, Urologic oncology.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression

T. Werner, V. Srikantan, I. Sesterhenn, 2012, Prostate Cancer and Prostatic Diseases.

Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells.

J. Rhim, S. Srivastava, D. Mcleod, 2008, Experimental cell research.

Gynecomastia in patients with prostate cancer: a review of treatment options.

P. Iversen, D. Mcleod, 2000, Urology.

Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy.

J. Moul, D. Mcleod, J. Bishop, 1990, Urology.

Combined low‐dose flutamide plus finasteride vs low‐dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long‐term follow‐up

E. Crawford, J. Moul, D. Mcleod, 2009, BJU international.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss

R. Howard, P. Harding, D. Mcleod, 2002, Prostate Cancer and Prostatic Diseases.

Advances made in the treatment of testicular cancer in the U.S. Military: 1946 to the present.

D. Mcleod, S. Brassell, D. Hawksworth, 2009, Urologic oncology.

Clinical predictors of response in metastatic germ cell tumors

N. Dawson, D. Mcleod, R. Knight, 1988, Cancer.

Leiomyosarcoma of the inferior vena cava presenting as a suprarenal mass.

D. Mcleod, D. Bloom, S. Skoog, 1983, The Journal of urology.

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Daniel J. Culkin, Patrick J. Loehrer, I. Thompson, 1998, New England Journal of Medicine.

Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases.

J. Thrasher, D. Mcleod, P. Langenstroer, 2004, The Journal of urology.

Experience with the AMS 600 malleable penile prosthesis.

J. Moul, D. Mcleod, 1986, The Journal of urology.

Use of Glycosylated Hemoglobin to Identify Diabetics at High Risk for Penile Periprosthetic Infections

J. Moul, D. Mcleod, D. Peppas, 1992 .

Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.

D. Wood, M. Soloway, D. Mcleod, 1995, The Journal of urology.

PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.

E. Klein, J. Peabody, M. Soloway, 1997, Urology.

Extragonadal Germ Cell Tumors

J. Waxman, N. Dawson, D. Mcleod, 2006 .

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

J. Moul, C. Amling, W. Sexton, 2008, The Journal of urology.

Mutations of the p16 gene product are rare in prostate cancer

J. Moul, S. Srivastava, I. Sesterhenn, 1997, The Prostate.

Celiac axis and superior mesenteric artery injury associated with left radical nephrectomy for locally advanced renal cell carcinoma.

J. Moul, D. Mcleod, J. Foley, 1991, The Journal of urology.

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

I. Thompson, G. Miller, G. Wilding, 1998, The New England journal of medicine.

Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival

S. Srivastava, Y. Shi, D. Mcleod, 2006, Oncogene.

Cost‐effective models for flutamide for prostate carcinoma patients: Are they helpful to policy makers?

B. Hillner, D. Matchar, D. Mccrory, 1996, Cancer.

Chronic orchialgia in the pain prone patient: the clinical perspective.

D. Mcleod, R. Costabile, M. Hahn, 1991, The Journal of urology.

Silent renal obstruction with severe functional loss after extracorporeal shock wave lithotripsy: a report of 2 cases.

D. Mcleod, M. Hardy, 1987, The Journal of urology.

Candida albicans corpora abscess following penile prosthesis placement.

J. Moul, D. Mcleod, D. Peppas, 1988, Journal of Urology.

Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin.

J. Rhim, S. Srivastava, D. Mcleod, 2007, International journal of oncology.

Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.

F. Mostofi, J. Moul, S. Srivastava, 1996, Surgery.

Anaplastic seminoma. An analysis of 77 patients

J. Clements, D. Mcleod, F. Cardinale, 1979, Cancer.

The clinical significance of unconventional orchiectomy approaches in testicular cancer: a report from the Testicular Cancer Intergroup Study.

D. Stablein, R. Weiss, D. Mcleod, 1988, The Journal of urology.

Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen.

J. Moul, D. J. Lewis, D. Mcleod, 1994, Urology.

Radiation therapy: a primary treatment modality for seminoma.

D. Mcleod, R. Stutzman, 1980, The Urologic clinics of North America.

Radiation therapy for nonseminomatous germ cell tumors of the testis: a reappraisal.

J. Clements, D. Mcleod, R. Stutzman, 1981, The Journal of urology.

Critical appraisal of routine supraclavicular lymph node biopsy in staging of testicular tumors.

D. Mcleod, J. Fowler, R. Stutzman, 1979, Urology.

Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man.

F. Mostofi, J. Moul, D. Mcleod, 1994, The Journal of urology.

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence

S. Srivastava, I. Sesterhenn, S. Srivastava, 2019, Oncotarget.

Genetic and Molecular Differences in Prostate Carcinogenesis between African American and Caucasian American Men

S. Srivastava, G. Petrovics, D. Mcleod, 2013, International journal of molecular sciences.

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

S-H Tan, S. Srivastava, I. Sesterhenn, 2010, Prostate Cancer and Prostatic Diseases.

Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2008, Modern Pathology.

Prognostic features of Annexin A2 expression in prostate cancer.

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2020, Pathology.

ERG oncogene modulates prostaglandin signaling in prostate cancer cells

S. Srivastava, I. Sesterhenn, Hua Li, 2011, Cancer biology & therapy.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

V. Srikantan, J. Moul, S. Srivastava, 2005, Oncogene.

Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer

Chen Sun, S. Srivastava, I. Sesterhenn, 2008, Clinical Cancer Research.

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men

Z. Szallasi, M. Loda, I. Csabai, 2015, EBioMedicine.

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer

S. Srivastava, I. Sesterhenn, Hua Li, 2014, Epigenetics.

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India

S. Srivastava, I. Sesterhenn, G. Petrovics, 2013, Journal of Cancer.

ERG Expression Levels in Prostate Tumors Reflect Functional Status of the Androgen Receptor (AR) as a Consequence of Fusion of ERG with AR Regulated Gene Promoters

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2010 .

Evaluation of ERG responsive proteome in prostate cancer

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2014, The Prostate.

Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.

J. Strovel, S. Srivastava, C. Dalgard, 2018, Cancer research.

Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells

S. Srivastava, Hua Li, E. Srivatsan, 2017, Molecular Cancer Research.

Evaluation of the 8q24 prostate cancer risk locus and MYC expression.

P. Kantoff, K. Ardlie, S. Wyman, 2009, Cancer research.

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag

S. Srivastava, I. Sesterhenn, S. Srivastava, 2016, Genes & cancer.

Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence

S. Srivastava, I. Sesterhenn, S. Srivastava, 2010, Prostate Cancer and Prostatic Diseases.

Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer

A. D'Amico, J. Richie, P. Carroll, 2006, Cancer.

Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy

J. Moul, S. Srivastava, J. Bauer, 1997, Cancer.

Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.

J. Moul, W. Mccarthy, D. Mcleod, 1996, The Journal of urology.

Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression

Cara C. Schafer, J. Moul, S. Srivastava, 2022, Scientific Reports.

Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells

Wei Zhang, Wei Zhang, J. Moul, 2002, Oncogene.

Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology.

S. Srivastava, I. Sesterhenn, S. Shirasawa, 2010, Urology.

PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.

W. Zhang, M. Augustus, V. Srikantan, 2000, Cancer research.

A novel neoplastic primary tumor-derived human prostate epithelial cell line.

J. Rhim, J. Moul, S. Srivastava, 2003, International journal of oncology.

Hepatic subcapsular extension of pelvic lymphocele after radical retropubic prostatectomy.

D. Mcleod, J. Bauer, 1998, Urology.

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2009, Prostate Cancer and Prostatic Diseases.

Cost-effective uroflowmetry in men.

D. Mcleod, D. Bloom, R. Stutzman, 1985, The Journal of urology.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2008, The Journal of urology.

Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.

F. Mostofi, J. Moul, S. Srivastava, 1996, The Journal of urology.

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Nan Zhang, Amina Ali, P. Febbo, 2015, European urology.

Quantitative expression profile of androgen‐regulated genes in prostate cancer cells and identification of prostate‐specific genes

J. Moul, S. Srivastava, D. Mcleod, 2001, International journal of cancer.

Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines.

W. Isaacs, C. Ewing, J. Rhim, 2006, Experimental cell research.

Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.

J. Moul, C. Amling, C. Kane, 2003, International journal of radiation oncology, biology, physics.

Predominance of ERG-negative high-grade prostate cancers in African American men.

S. Srivastava, I. Sesterhenn, S. Srivastava, 2014, Molecular and clinical oncology.

A novel human cancer culture model for the study of prostate cancer

J. Rhim, J. Moul, S. Srivastava, 2001, Oncogene.

Prostate Cancer A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low-and Intermediate-risk Prostate Cancer

P. Febbo, S. Srivastava, I. Sesterhenn, 2015 .

Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.

J. Rhim, S. Srivastava, I. Sesterhenn, 2007, Cancer research.

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years

M. Wirth, W. See, P. Iversen, 2010, BJU international.

Comparison of Megace, Stilphostrol, Megace plus DES, or streptozotocin in metastatic prostatic cancer in patients with hormonal failure and prior radiotherapy.

R. Priore, G. Murphy, D. Mcleod, 1989, Urology.

Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover

J. Moul, G. Striker, L. Nyberg, 2003, Prostate Cancer and Prostatic Diseases.

Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.

A. D'Amico, P. Kantoff, D. Lubeck, 2002, Urology.

Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat.

Yongmei Chen, D. Mcleod, M. Colombo, 2013, Urologic oncology.

Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study.

E. Messing, R. Bahnson, M. Ernstoff, 1995, The Journal of urology.

Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy.

J W Moul, J. Moul, J. Thrasher, 2000, The Journal of urology.

The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.

J. Moul, R. Connelly, D. Mcleod, 1998, The Journal of urology.

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

A. D'Amico, P. Carroll, Ming-Hui Chen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer

H. Parnes, J. Trepel, W. Figg, 2015, BJU international.

A phase I study of TRC 105 anti-endoglin ( CD 105 ) antibody in metastatic castration-resistant prostate cancer

H. Parnes, J. Trepel, W. Figg, 2015 .

Perioperative complications of radical retropubic prostatectomy.

D. Mcleod, S. Brassell, J. Sterbis, 2005, Clinical genitourinary cancer.

Prostatic trauma and release of acid phosphatase. Radioimmunochemical and enzymatic comparison.

J. Clements, D. Mcleod, D. Mahan, 1980, Urology.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression

T. Werner, V. Srikantan, S. Srivastava, 2011, Prostate Cancer and Prostatic Diseases.

Adrenal cortical carcinoma with vena cava tumor thrombus requiring cardiopulmonary bypass for resection.

J. Moul, D. Mcleod, M. Hardy, 1991, Urology.

p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein

W. Zhang, I. Sesterhenn, J. Moul, 2003, Prostate Cancer and Prostatic Diseases.

Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line.

J. Rhim, J. Moul, S. Srivastava, 2005, Anticancer research.

Prostate‐specific antigen‐detected prostate cancer (Stage T1c): An analysis of whole‐mount prostatectomy specimens

J. Moul, R. Connelly, I. Sesterhenn, 1997, The Prostate.

Inhibition of the growth of pre‐established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector

J. Moul, S. Srivastava, I. Sesterhenn, 1997, International journal of cancer.

EVALUATION OF REVERSE TRANSCRIPTASE (RT)-POLYMERASE CHAIN REACTION (PCR)-PROSTATE SPECIFIC ANTIGEN (PSA) ASSAY IN EPITHELIAL CELLS ISOLATED FROM PERIPHERAL BLOOD OF PROSTATE CANCER (CaP) PATIENTS

J. Moul, S. Srivastava, D. Mcleod, 1999 .

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

Hong Tang, Matthew R Cooperberg, Andrew J Armstrong, 2019, Cancer.

Clinicopathological behavior of single focus prostate adenocarcinoma.

I. Sesterhenn, Yongmei Chen, D. Mcleod, 2009, The Journal of urology.

Combined androgen blockade: the gold standard for metastatic prostate cancer.

E. Crawford, D. Mcleod, E. DeAntoni, 1997, European urology.

Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.

J. Serth, F. Mostofi, C. Bokemeyer, 2003, Oncology reports.

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

S. Srivastava, I. Sesterhenn, S. Perner, 2012, Urology.

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

P. Kantoff, M. Cooperberg, P. Schellhammer, 2020, Prostate Cancer and Prostatic Diseases.

Racial/Ethnic Patterns in Prostate Cancer Outcomes in an Active Surveillance Cohort

T. Brand, Yongmei Chen, D. Mcleod, 2011, Prostate cancer.

A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate.

J W Moul, J. Moul, S. Srivastava, 2000, Genomics.

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods

Richard D. Smith, S. Srivastava, D. Camp, 2015, Journal of Translational Medicine.

ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity.

S. Srivastava, S. Srivastava, A. Srinivasan, 2014, Monoclonal antibodies in immunodiagnosis and immunotherapy.

A Comparison of Leuprolide with Flutamide and Leuprolide in Previously Untreated Patients with Clinical Stage D2 Cancer of the Prostate, Phase III, Intergroup Study-0036

E. Crawford, A. Dorr, M. Eisenberger, 1987 .

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.

M. Wirth, W. See, P. Iversen, 2004, The Journal of urology.

Acute urinary retention associated with prostatic carcinoma.

J. Moul, D. Mcleod, R. Davis, 1989, The Journal of urology.

Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.

D. Wood, M. Soloway, K. Pareek, 2002, The Journal of urology.

Quantitative expression profile of PSGR in prostate cancer

J. Moul, I. Sesterhenn, W. Zhang, 2006, Prostate Cancer and Prostatic Diseases.

Low-velocity gunshot injury to ureter.

D. Mcleod, W. McDonald, 1978, Urology.

A case report: duplicated vena cava with right retrocaval ureter and ureteral tumor.

J. Clements, D. Mcleod, R. Stutzman, 1978, The Journal of urology.

Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.

A. D'Amico, P. Carroll, Ming-Hui Chen, 2006, Urology.

The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints.

N. Dawson, D. Mcleod, Nancy A. Dawson, 1997, European journal of cancer.

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.

Hongyu Wu, Judd W. Moul, David G. McLeod, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Malpractice claims for urogenital injuries.

T. Pendergrass, D. Mcleod, A. Morey, 1988, The Journal of urology.

Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing.

Laurence R. Paquette, J. Moul, R. Connelly, 2002, Urology.

External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence

J. Moul, R. Connelly, D. Mcleod, 2004, Prostate Cancer and Prostatic Diseases.

Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2017, European urology focus.

Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.

J. Moul, S. Srivastava, J. Bauer, 1998, The Journal of urology.

Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.

H. Klocker, G. Bartsch, R. Wolfert, 1998, Urology.

Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.

M. Wirth, W. See, P. Iversen, 2003, European urology.

Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data

P. Kantoff, M. Cooperberg, A. Armstrong, 2020, Cancer.

Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.

G. Petrovics, D. Mcleod, 2018, European urology.

Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at Prostatectomy

S. Srivastava, M. Freedman, Yongmei Chen, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes.

Yongmei Chen, D. Mcleod, J. Cullen, 2011, The Journal of urology.

The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate

P. Scardino, S. Loening, G. Murphy, 1983, Journal of surgical oncology.

The burden of prostate cancer in Asian nations

Yongmei Chen, D. Mcleod, M. Colombo, 2012, Journal of carcinogenesis.

Radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in CT2B prostate cancer -24 month results

D. Wood, M. Soloway, D. Mcleod, 1997 .

Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors.

P. Albert, D. Mcleod, R. Wilder, 2005, The Journal of urology.

Tolerability of Antiandrogens in the Treatment of Prostate Cancer

D. Mcleod, R. Fourcade, 2004 .

Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.

B. Trock, Jiji Jiang, M. Eisenberger, 2021, The Journal of urology.

High Intensity Focused Ultrasound for Radiorecurrent Prostate Cancer: A North American Clinical Trial

Joseph Chin, Leonard S Marks, J. Chin, 2018, The Journal of urology.

The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.

J. Montie, W. See, G. Chodak, 2006, The Journal of urology.

Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer

D. Wood, M. Soloway, D. Mcleod, 1995 .

Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer.

C Coley, P. Schellhammer, I. Thompson, 2001, Urology.

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

P. Kantoff, M. Cooperberg, P. Schellhammer, 2020, Prostate Cancer and Prostatic Diseases.

HORMONAL TREATMENT BEFORE RADICAL PROSTATECTOMY: A 3-YEAR FOLLOWUP

D. Mcleod, 1998 .

Hormonal therapy: historical perspective to future directions.

D. Mcleod, David G Mcleod, 2003, Urology.

Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.

J. Bishoff, J. Moul, C. Kane, 2003, Urology.

Prostate cancer in men less than the age of 50: a comparison of race and outcomes.

Yongmei Chen, D. Mcleod, J. Cullen, 2011, Urology.

Bilateral organ-limited amyloidosis of the distal ureter associated with osseous metaplasia and radiographic calcification.

J. Moul, D. Mcleod, 1988, The Journal of urology.

Risk factors for perineal seeding of prostate cancer after needle biopsy.

J. Moul, B. Miles, D. Mcleod, 1989, The Journal of urology.

Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment.

D. Mcleod, S. Brassell, K. Rice, 2010, Reviews in urology.

810: Bicalutamide 150 MG Alone or as Adjuvant to Standard Care Significantly Improves Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer (Median 5.4 Years' Follow-Up)

M. Wirth, W. See, P. Iversen, 2004 .

1062: Bicalutamide 150 mg in Addition to Standard Care Significantly Improves Prostate Specific Antigen Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer: Median 5.4 Years' follow-up

M. Wirth, W. See, P. Iversen, 2004 .

180 Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non-metastatic prostate cancer: Updated analysis at a median 5.4 years' follow-up

M. Wirth, W. See, P. Iversen, 2004 .

182 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy significantly improves progression-free survival in early non-metastatic prostate cancer: Results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow-up

M. Wirth, W. See, P. Iversen, 2004 .

Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen.

E. Leifer, J. Moul, G. Murphy, 1996, Urology.

Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA

E. Leifer, J. Moul, G. Murphy, 1996, The Prostate. Supplement.

Editorial: Prostate Cancer

D. Mcleod, 1995 .

1184: How Long can Radical Prostatectomy (RP) Safely be Delayed? CPDR'S Experiences From 3324 Cases

Ken R. Smith, J. Moul, C. Amling, 2004 .

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

A. D'Amico, P. Carroll, Ming-Hui Chen, 2008, Urology.

Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up.

P. Schellhammer, I. Thompson, A. Zietman, 2001, Urology.

Prostate cancer in men under the age of 50: A comparison of race and outcomes.

Yongmei Chen, D. Mcleod, S. Brassell, 2010 .

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2020, Journal of Translational Medicine.

The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.

John T. Wei, A. D'Amico, P. Schellhammer, 2010, Urology.

Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer.

A W Partin, E J Gamito, A. Partin, 2001, Urology.

A comparison of testicular tumors in black and white patients.

D. Mcleod, R. Stutzman, J. L. Daniels, 1981, Journal of Urology.

Re: Antibody-Based Detection of ERG Rearrangement- Positive Prostate Cancer Park K, Tomlins SA, Mudaliar KM, et al

D. Mcleod, Albert Dobib, 2011 .

Postoperative myocardial infarction after radical cystoprostatectomy masked by patient-controlled analgesia.

D. Mcleod, M. J. Finger, 1995, Urology.

Time to an undetectable prostate‐specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer‐specific mortality

A. D'Amico, Ming-Hui Chen, D. Mcleod, 2007, Cancer.

441: Pathologic Variables and Recurrence Rates as Related to Obesity and Race in Men with Prostate Cancer Undergoing Radical Prostatectomy

J. Moul, C. Amling, W. Sexton, 2004 .

Antiandrogenic drugs

D. Mcleod, 1993, Cancer.

Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients

J. Moul, I. Sesterhenn, D. Mcleod, 1997, Cancer.

Lymphovascular invasion in prostate cancer

P. Albert, D. Mcleod, M. Poggi, 2006, Cancer.

Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.

E. Leifer, J. Moul, J. Bauer, 1999, Urology.

Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

S. Steinberg, J. Trepel, J. Wright, 2015 .

Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994.

J. Moul, J. Bauer, D. Mcleod, 1996, Military medicine.

Sipuleucel-T in African Americans: A subgroup analysis of three phase III sipuleucel-T trials in advanced prostate cancer.

D. Quinn, D. Mcleod, J. Whitmore, 2011, Journal of Clinical Oncology.

The design and implementation of a multidisciplinary prostate cancer clinic.

R. P. Hudak, D. Mcleod, S. Brassell, 2007, Urologic nursing.

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer

S. Srivastava, I. Sesterhenn, S. Srivastava, 2014, Genes & cancer.

Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer.

J. Moul, J. Bauer, R. Connelly, 1998, Military medicine.

Colorectal Prostate Skin Cancer Screening Among Hispanic White Non-Hispanic Men 2000–2005

J. Potter, S. Steele, A. Stojadinovic, 2011 .

Thymic hyperplasia in newly diagnosed testicular germ cell tumors.

J. Moul, D. Mcleod, C. K. Ho, 1994, The Journal of urology.

D. Mcleod, J. Cullen, S. Brassell, 2013, Urologic oncology.

Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer

S. Srivastava, I. Sesterhenn, S. Miick, 2010, Clinical Cancer Research.

Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2007, Urology.

Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues.

D. Mcleod, 2008, European urology.

Decade-long Trends in Prostate Cancer Incidence and Mortality in Poland, 1999–2012

D. Mcleod, L. Hurwitz, J. Cullen, 2018 .

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Jeonifer M. Garren, S. Srivastava, E. Diamandis, 2021, Scientific Reports.

Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study.

J. Oesterling, E. Crawford, N. Stone, 1996, Urology.

Patient selection for experimental adjuvant therapy after radical prostatectomy.

J. Moul, W. Mccarthy, D. Mcleod, 1996, Urology.

152 ALL-CAUSE MORTALITY AMONG MILITARY HEALTH CARE BENEFICIARIES WITH PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE

S. Srivastava, Yongmei Chen, D. Mcleod, 2011 .

Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer.

John A. Taylor, D. Mcleod, Kevin J Gancarczyk, 2002, Urology.

ERG Expression Levels in Prostate Tumors Reflect Functional Status ofthe Androgen Receptor (AR) as a Consequence of Fusion of ERG with ARRegulated Gene Promoters

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2010 .

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods

Richard D. Smith, S. Srivastava, D. Camp, 2015, Journal of Translational Medicine.

Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles.

J. Rhim, T. Hei, D. Mcleod, 2007, International journal of oncology.

Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.

P. Kantoff, M. Cooperberg, P. Schellhammer, 2019, Journal of Clinical Oncology.

Long-term follow-up assessment of a HER-2/neu peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patients

E. Mittendorf, G. Peoples, D. Mcleod, 2008 .

Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.

T. Brand, A. Metwalli, Yongmei Chen, 2014, Urologic oncology.

Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat.

Yongmei Chen, D. Mcleod, J. Cullen, 2013, Urologic oncology.

Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer

S. Srivastava, I. Sesterhenn, S. Miick, 2010, Clinical Cancer Research.

Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer

D. Wood, M. Soloway, D. Mcleod, 1995 .

D. Wood, M. Soloway, D. Mcleod, 1995, The Journal of urology.

Prostate‐specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer

A. D'Amico, Yongmei Chen, D. Mcleod, 2007, Cancer.

Prostate cancer in men less than the age of 50: a comparison of race and outcomes.

Yongmei Chen, D. Mcleod, J. Cullen, 2011, Urology.

The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma

A W Partin, E D Crawford, E J Gamito, 2000, Cancer.

An assessment of the virtual conversations method for prostate cancer patient education.

W. Harless, D. Mcleod, R. C. Duncan, 2007, Urologic nursing.